Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour
Andrew J. Wagner, Mark Agulnik, Michael C. Heinrich, Daruka Mahadevan, Richard F. Riedel, Margaret Von Mehren, Jonathan Trent, George D. Demetri, Christopher L. Corless, Murray Yule, John F. Lyons, Aram Oganesian, Harold Keer
Dive into the research topics of 'Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour'. Together they form a unique fingerprint.